Amedisys Logo
US0234361089

Amedisys

Ins Portfolio

Kurse werden geladen...

 Anzeige

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +139,14(+55,90%). Der Median liegt bei +157,69(+76,68%).

Kaufen
  4
Halten
  6
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie0 / 15
HGI-Strategie8 / 18
Levermann-Strategie-3 / 13
Powered byaktien.guide

News

  • Foto von UnitedHealth's $3.3B Merger Stalls as VitalCaring Sale Falls Through

    UnitedHealth's $3.3B Merger Stalls as VitalCaring Sale Falls Through

    UNH and AMED are now expected to identify new buyers for the divestment assets by March 2025.» Mehr auf zacks.com

  • Foto von Reasons to Retain AMED Stock in Your Portfolio Now

    Reasons to Retain AMED Stock in Your Portfolio Now

    Amedisys' expected merger with UnitedHealth Group's Optum brings optimism to investors. Yet, a dull macroeconomic condition adds to the worry.» Mehr auf zacks.com

  • Foto von Midnight Sun Mining secures Kazhiba target license renewal - ICYMI

    Midnight Sun Mining secures Kazhiba target license renewal - ICYMI

    Midnight Sun Mining Corp (TSX-V:MMA, OTCQB:MDNGF) director of marketing and communications Adrian O'Brien talked with Proactive about securing approval from Zambia's Mines Ministry for the renewal of the Kazhiba target license. He emphasized that the license is a cornerstone of the cooperative exploration plan with First Quantum Minerals (TSX:FM). Proactive: Exciting news about the company’s license renewal for your Kazhiba target. This is really the end of a long journey. Can you bring everyone up to date on where things stand? Adrian O'Brien: Certainly. We've just received approval from the Mines Ministry of Zambia for the renewal of the license covering our Kazhiba target. This is a crucial part of our cooperative exploration plan with First Quantum Minerals. We've been waiting for this approval for some time due to a clerical error last summer, which showed the license as rejected. Thankfully, the Zambian ministry was great, and the situation has been resolved. This renewal sets us up perfectly for moving forward. Now that you have the license in hand, what are the next steps for the company over the next three to six months? This approval is pivotal for our cooperative exploration with First Quantum. We have two primary targets—Kazhiba to the northwest and Mitu to the southwest of our property. Both have significant oxide copper concentrations at surface, identified through drilling. The plan is to continue exploration work to prove up resources. We’ve already started, and this renewal allows us to push forward, complete programs, and deliver results. We expect to announce assay results soon, so exciting times are ahead. You also mentioned near-term production opportunities and potential cash flow. Could you elaborate? Certainly. Kansanshi, First Quantum's flagship mine, is located about six kilometers from our property. It's the largest copper mining complex in Africa and has been operational for 20 years. However, its oxide copper supply has been depleted. Our property is now the only source of high-concentration oxides in the area. We aim to address their supply issues and support their operations for the next 5 to 10 years. Finally, there’s news about your agreement with Kobold Mining. Can you update us on that? Yes. We’ve amended the earning agreement to remove the long stop date. This gives us more flexibility to obtain the required environmental permits without repeatedly extending deadlines. We’re looking to start drilling aggressively after the rainy season, around March or April. Quotes have been lightly edited for clarity and style UnitedHealth Group Inc (NYSE:UNH, ETR:UNH) and Amedisys (NASDAQ:AMED) have agreed to extend the deadline for their $3.3 billion merger, facing ongoing scrutiny from the US Department of Justice (DOJ). The companies announced in a regulatory filing that the merger deadline will now be extended to 10 days after a final court decision is issued or December 31, 2025, whichever comes first. This development follows a lawsuit filed over a month ago by the DOJ and attorneys general from Maryland, New Jersey, and New York to block the merger. Regulators argue that the deal would reduce competition in the home health services market, potentially harming patients, insurers, and nurses. The original deadline for the merger was set for today. Under a new waiver agreement, the companies have adjusted financial terms, including a regulatory break fee of $275 million, which could rise to $325 million if specific asset divestitures are not completed by May 1. Other modifications to the agreement include changes to operational restrictions and conditions tied to government approvals. UnitedHealth first announced plans to acquire Amedisys in June 2023, seeking to integrate the home health and hospice care provider into its operations. Despite the regulatory challenges, the companies remain committed to completing the deal, which they believe will deliver significant synergies and growth opportunities. Shares of Amedisys added 4.7% at $90 on the update, while UnitedHealth stock was down 0.5% at about $508.» Mehr auf proactiveinvestors.com

Dividenden

Alle Kennzahlen
In 2022 hat Amedisys +66,49 Dividende ausgeschüttet. Die letzte Dividende wurde im Mai 2022 gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Amedisys einen Umsatz von +527,71 Mio und ein Nettoeinkommen von +37,23 Mio
(EUR)Sep. 2024
YOY
Umsatz+527,71 Mio0,43%
Bruttoeinkommen+224,59 Mio2,80%
Nettoeinkommen+37,23 Mio51,82%
EBITDA+23,34 Mio52,52%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+2,92 Mrd
Anzahl Aktien
32,75 Mio
52 Wochen-Hoch/Tief
+96,02 - +79,72
DividendenNein
Beta
0,78
KGV (PE Ratio)
+23,60
KGWV (PEG Ratio)
+1,73
KBV (PB Ratio)
+2,62
KUV (PS Ratio)
+1,30

Unternehmensprofil

Amedisys, Inc. bietet zusammen mit seinen Tochtergesellschaften Gesundheitsdienstleistungen in den Vereinigten Staaten an. Das Unternehmen ist in drei Segmenten tätig: Häusliche Krankenpflege, Hospiz, Persönliche Pflege und Hochintensivpflege. Das Segment Häusliche Krankenpflege bietet eine Reihe von Dienstleistungen in den Häusern von Einzelpersonen zur Genesung von Patienten nach Operationen, chronischen Behinderungen oder unheilbaren Krankheiten an und verhindert vermeidbare Krankenhauseinweisungen durch qualifizierte Krankenschwestern, Rehabilitationstherapeuten, die auf Physio-, Sprach- und Beschäftigungstherapie spezialisiert sind, sowie Sozialarbeiter und Hilfskräfte zur Unterstützung der Patienten. Das Segment Hospiz bietet Dienstleistungen an, die Menschen, die an einer unheilbaren Krankheit wie Krebs, Herz- oder Lungenkrankheiten oder Alzheimer leiden, Trost und Unterstützung bieten sollen. Das Segment Persönliche Pflege bietet Unterstützung für Patienten bei den Aktivitäten des täglichen Lebens. Der Bereich High Acuity Care bietet wesentliche Elemente der stationären Krankenhauspflege, der Pflege in qualifizierten Pflegeeinrichtungen und der Palliativpflege für Patienten in ihrem Zuhause an. Zum 31. Dezember 2021 besaß und betrieb das Unternehmen 331 Zentren für häusliche Krankenpflege, 175 Zentren für Hospizpflege, 14 Zentren für persönliche Pflege und 8 Zentren für Intensivpflege in 38 Bundesstaaten der Vereinigten Staaten und im District of Columbia. Amedisys, Inc. wurde 1982 gegründet und hat seinen Hauptsitz in Baton Rouge, Louisiana.

Name
Amedisys
CEO
Richard M. Ashworth
SitzBaton Rouge, la
USA
Website
Industrie
Gesundheitswesen: Anbieter und Dienstleister
Börsengang
12.09.2018
Mitarbeiter19.000

Ticker Symbole

BörseSymbol
NASDAQ
AMED
Frankfurt
ADY.F
Düsseldorf
ADY.DU
SIX
ADY.SW
München
ADY.MU

Assets entdecken

Shareholder von Amedisys investieren auch in folgende Assets

🍪

Parqet nutzt Cookies.Erfahre Mehr